Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trial

21 Feb 2023

Abstract excerpt

Group B streptococcus (GBS) is a leading cause of life-threatening neonatal infections and subsets of adverse pregnancy outcomes. Essentially all GBS strains possess one allele of the alpha-like protein (Alp) family. A maternal GBS vaccine, consisting of the fused N-terminal domains of the Alps αC and Rib (GBS-NN), was recently demonstrated to be safe and immunogenic in healthy adult women. To enhance antibody...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neonatal and Maternal Infections
Share to Pneumonia and Respiratory Infections
Share to Streptococcal Infections and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36915681
DOI: 10.1016/j.isci.2023.106261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and immunogenicity of the group B streptococcus vaccine AlpN in a placebo-controlled double-blind phase 1 trialPMID 36915681Read ↗

Safety and immunogenicity of a prototype recombinant alpha-like protein subunit vaccine (GBS-NN) against Group B Streptococcus in a randomised placebo-controlled double-blind phase 1 trial in healthy adult womenSemantic proximity Read ↗

Progress toward a group B streptococcal vaccineSemantic proximity Read ↗

Potential for Maternally Administered Vaccine for Infant Group B StreptococcusSemantic proximity Read ↗

The Development of a Vaccine Against Meningococcus B Using Reverse VaccinologySemantic proximity Read ↗

Update on the development of Group A Streptococcus vaccinesSemantic proximity Read ↗

Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countriesSemantic proximity Read ↗

<i>Neisseria meningitidis</i>serogroup B bivalent factor H binding protein vaccineSemantic proximity Read ↗

The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine designSemantic proximity Read ↗

The Group A Streptococcal Vaccine Candidate VAX-A1 Protects against Group B Streptococcus Infection via Cross-Reactive IgG Targeting Virulence Factor C5a PeptidaseSemantic proximity Read ↗

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteinsSemantic proximity Read ↗

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.Semantic proximity Read ↗

OpcA and PorB are novel bactericidal antigens of the 4CMenB vaccine in mice and humansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.